pmid	doi	year	title	Hugo_Symbol
32401663	10.1080/15513815.2020.1764680	2022	PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance?	CD274
33722840	10.1136/jclinpath-2020-207280	2022	Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).	CD274
33870634	10.1111/ajco.13549	2022	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration samples for programmed death ligand-1 testing in non-small cell lung cancer, the Bristol experience.	CD274
34520052	10.1111/bjh.17793	2022	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.	CD274
34585994	10.1080/10428194.2021.1984454	2022	Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.	CD274
34841687	10.1111/1759-7714.14216	2022	Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.	CD274
34842351	10.1002/cam4.4462	2022	PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.	CD274
34862664	10.1111/apm.13195	2022	Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.	CD274
34903527	10.1101/gr.275911.121	2022	Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers.	CD274
34936940	10.1016/j.ejca.2021.11.013	2022	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.	CD274
34959071	10.1016/j.molimm.2021.12.014	2022	HomA and HomB, outer membrane proteins of Helicobacter pylori down-regulate activation-induced cytidine deaminase (AID) and Ig switch germline transcription and thereby affect class switch recombination (CSR) of Ig genes in human B-cells.	CD274
34968160	10.1080/21655979.2021.2014617	2022	microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.	CD274
34996890	10.1038/s41598-021-02515-5	2022	The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.	CD274
35032188	10.1007/s00277-022-04760-8	2022	Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.	CD274
35165282	10.1038/s41467-022-28479-2	2022	EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.	CD274
35194801	10.1111/bjd.21063	2022	Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome.	CD274
35344582	10.1182/blood.2021014007	2022	Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.	CD274
35359004	10.1182/bloodadvances.2022007104	2022	SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.	CD274
35373781	10.23736/S2784-8671.22.07275-9	2022	PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome.	CD274
35417939	10.3324/haematol.2021.280352	2022	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.	CD274
35443604	10.7754/Clin.Lab.2021.210701	2022	Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.	CD274
35644823	10.1186/s43046-022-00121-8	2022	The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.	CD274
35655072	10.1038/s41598-022-13101-8	2022	Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL.	CD274
35680804	10.19746/j.cnki.issn.1009-2137.2022.03.018	2022	[Inhibitory Effect of Interference with PD-L1 Expression on B-cell lymphoma in Mice].	CD274
35741318	10.3390/diagnostics12061507	2022	Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.	CD274
35764886	10.1038/s41598-022-15162-1	2022	Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.	CD274
35767735	10.1182/bloodadvances.2022007046	2022	The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.	CD274
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	CD274
35789115	10.1111/his.14718	2022	Hodgkinoid histiocytosis: an atypical nodal CD30 and S100-positive histiocytosis with eosinophilia.	CD274
35848760	10.1097/PAS.0000000000001899	2022	9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions.	CD274
35922773	10.1186/s12885-022-09803-x	2022	Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.	CD274
31608729	10.1080/10428194.2019.1675880	2021	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia.	CD274
32803453	10.1007/s00428-020-02901-w	2021	Clinicopathological analysis of neoplastic PD-L1-positive EBV<sup>+</sup> diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort.	CD274
32815748	10.1080/0284186X.2020.1806358	2021	Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014.	CD274
32871584	10.1182/blood.2020006464	2021	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.	CD274
32964767	10.1080/10428194.2020.1821011	2021	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.	CD274
33028589	10.1158/1078-0432.CCR-20-1457	2021	CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.	CD274
33091534	10.1016/j.canlet.2020.10.024	2021	NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.	CD274
33184699	10.1007/s00262-020-02787-2	2021	Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma.	CD274
33196892	10.1007/s00432-020-03444-y	2021	Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.	CD274
33232972	10.1182/blood.2020005244	2021	Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.	CD274
33247999	10.1111/cas.14752	2021	Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.	CD274
33277223	10.1016/j.clml.2020.11.009	2021	Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.	CD274
33299141	10.1038/s41375-020-01105-0	2021	Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.	CD274
33369766	10.1002/hon.2836	2021	Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.	CD274
33389078	10.1007/s00432-020-03446-w	2021	Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.	CD274
33454550	10.1016/j.ejmech.2021.113170	2021	Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.	CD274
33480087	10.1002/hon.2839	2021	High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.	CD274
33512416	10.1182/blood.2020007245	2021	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.	CD274
33517324	10.2967/jnumed.120.258384	2021	Synthesis and Preclinical Evaluation of a <sup>68</sup>Ga-Labeled Adnectin, <sup>68</sup>Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression.	CD274
33558066	10.1016/j.pathol.2020.11.004	2021	CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.	CD274
33560388	10.1182/bloodadvances.2020002371	2021	Pembrolizumab in mycosis fungoides with PD-L1 structural variants.	CD274
33590326	10.1007/s00595-021-02236-2	2021	Immunotherapeutic advances in gastric cancer.	CD274
33620088	10.1111/bjh.17362	2021	Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.	CD274
33655698	10.1002/cam4.3649	2021	Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.	CD274
33674274	10.1158/1078-0432.CCR-21-0133	2021	Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.	CD274
33686666	10.1111/bjh.17366	2021	Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.	CD274
33691262	10.1016/j.ejca.2021.01.020	2021	Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.	CD274
33721375	10.1111/ejh.13621	2021	Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.	CD274
33764958	10.12659/MSM.929431	2021	Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.	CD274
33807678	10.3390/jof7030186	2021	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.	CD274
33847923	10.1007/s12094-021-02579-9	2021	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).	CD274
33889438	10.1080/2162402X.2021.1907059	2021	VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.	CD274
33918793	10.3390/cancers13081801	2021	Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets.	CD274
33941556		2021	PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.	CD274
33972504	10.1038/s41408-021-00477-5	2021	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.	CD274
34021249	10.1038/s41375-021-01289-z	2021	Thyroid MALT lymphoma: self-harm to gain potential T-cell help.	CD274
34060602	10.1042/BSR20204186	2021	Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.	CD274
34077007		2021	Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.	CD274
34078046	10.3760/cma.j.cn112151-20201223-00953	2021	[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].	CD274
34125179	10.1182/blood.2021011366	2021	Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.	CD274
34130989	10.1136/jitc-2021-002558	2021	Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.	CD274
34153661	10.1016/j.intimp.2021.107870	2021	PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.	CD274
34181355	10.31557/APJCP.2021.22.6.1943	2021	NFATc1 is Suppressed in Tumor Microenvironment of Hodgkin Lymphoma.	CD274
34257603	10.3389/pore.2021.637745	2021	Case Report: A Case Report of a Histological Transformation of <i>ALK</i>-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.	CD274
34327781	10.1111/cas.15091	2021	Current progress and future perspectives of research on intravascular large B-cell lymphoma.	CD274
34363798	10.1016/j.humpath.2021.07.011	2021	Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.	CD274
34405609	10.3760/cma.j.cn112151-20210110-00023	2021	[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].	CD274
34534136	10.1097/PAS.0000000000001809	2021	Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.	CD274
34543472	10.1002/hon.2926	2021	Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.	CD274
34558414	10.5152/balkanmedj.2021.20086	2021	Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.	CD274
34584457	10.2147/CMAR.S317319	2021	Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.	CD274
34600407	10.1016/j.lungcan.2021.09.011	2021	Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.	CD274
34615710	10.1073/pnas.2105822118	2021	Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.	CD274
34649362	10.1016/j.biopha.2021.112238	2021	An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers.	CD274
34661162	10.1158/2643-3230.BCD-21-0044	2021	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1.	CD274
34742294	10.1186/s13000-021-01163-7	2021	Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.	CD274
34955650	10.2147/IJGM.S341557	2021	Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma.	CD274
30225784	10.1007/s12253-018-0469-6	2020	The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.	CD274
31163235	10.1016/j.jaad.2019.05.077	2020	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review.	CD274
31330525	10.1159/000500974	2020	Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.	CD274
31383967	10.1038/s41379-019-0336-3	2020	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.	CD274
31493237	10.1007/s00535-019-01616-3	2020	Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.	CD274
31532724	10.1200/JCO.19.01056	2020	Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.	CD274
31598903	10.1007/s12094-019-02218-4	2020	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.	CD274
31653980	10.1038/s41379-019-0392-8	2020	Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.	CD274
31699300	10.1016/j.pathol.2019.09.005	2020	Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis.	CD274
31709594	10.1002/cbf.3463	2020	Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.	CD274
31747139	10.1002/cam4.2670	2020	A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.	CD274
31752573	10.1080/10428194.2019.1691200	2020	New murine models of aggressive lymphoma.	CD274
31787352	10.1016/j.imbio.2019.11.007	2020	Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.	CD274
31790142	10.1182/blood.2019000847	2020	The immune landscape and response to immune checkpoint blockade therapy in lymphoma.	CD274
31809310	10.1097/PAI.0000000000000798	2020	Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.	CD274
31811434	10.1007/s00428-019-02695-6	2020	Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.	CD274
31812554	10.1016/S1470-2045(19)30671-0	2020	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.	CD274
31825135	10.1002/1878-0261.12616	2020	High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination.	CD274
31829043	10.2217/fon-2019-0468	2020	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.	CD274
31879046	10.1016/j.prp.2019.152703	2020	TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas.	CD274
31894883	10.1111/pin.12891	2020	Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases.	CD274
31894892	10.1111/pin.12888	2020	Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry.	CD274
31903640	10.1002/jcla.23173	2020	Adrenal diffuse large B-cell lymphoma with high PD-L1 expression: Two case reports and literature review.	CD274
31911188	10.1016/j.semcancer.2020.01.001	2020	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance.	CD274
31911474	10.1073/pnas.1908158117	2020	High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.	CD274
31939183	10.1007/978-1-0716-0247-8_18	2020	Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-γ-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA.	CD274
31959728	10.1136/jitc-2019-000376	2020	Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in <i>EGFR</i> <i>/</i> <i>ALK</i> wild-type advanced non-small cell lung cancer.	CD274
31977037	10.1093/ajcp/aqz198	2020	Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.	CD274
31983543	10.1016/j.beem.2019.101370	2020	New insight in endocrine-related adverse events associated to immune checkpoint blockade.	CD274
31989260	10.1007/s00428-020-02756-1	2020	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.	CD274
31992262	10.1186/s12885-020-6550-z	2020	Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.	CD274
32030732	10.1111/bjh.16494	2020	Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.	CD274
32054467	10.1186/s12885-020-6612-2	2020	Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.	CD274
32066566	10.1158/0008-5472.CAN-19-2948	2020	Revisiting Immunotherapy: A Focus on Prostate Cancer.	CD274
32089543	10.1038/s41375-020-0737-9	2020	PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.	CD274
32108600	10.4103/lungindia.lungindia_488_19	2020	Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer.	CD274
32116068	10.1080/17474086.2020.1733405	2020	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.	CD274
32143684	10.1186/s13104-020-04975-w	2020	Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.	CD274
32157792	10.1002/1878-0261.12664	2020	Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma.	CD274
32170448	10.1007/s00428-020-02790-z	2020	Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.	CD274
32227409	10.1111/cas.14397	2020	In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.	CD274
32248797	10.1186/s12885-020-06755-y	2020	PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.	CD274
32268011	10.1002/cyto.b.21879	2020	Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.	CD274
32295735	10.1016/j.clml.2019.11.021	2020	The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.	CD274
32327170	10.1016/j.thorsurg.2020.01.011	2020	Current Landscape of Personalized Therapy.	CD274
32366559		2020	Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.	CD274
32367674	10.1002/cam4.3104	2020	PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.	CD274
32386255	10.1634/theoncologist.2020-0088	2020	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.	CD274
32394185	10.1007/s11899-020-00589-y	2020	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.	CD274
32424876	10.1111/pin.12950	2020	PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.	CD274
32515093	10.1002/hon.2758	2020	Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.	CD274
32558897	10.1084/jem.20191712	2020	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.	CD274
32591311	10.1016/j.cllc.2020.05.004	2020	Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.	CD274
32623805	10.1111/pin.12982	2020	Nodal diffuse large B-cell lymphoma with neoplastic PD-L1 positivity, but without EBV association: Three cases highlighting an aspect of gray zone lymphoma.	CD274
32627031	10.3892/or.2020.7643	2020	Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).	CD274
32649320	10.1097/PAS.0000000000001524	2020	PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.	CD274
32650968	10.1016/j.patol.2019.11.004	2020	[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].	CD274
32667831	10.1200/JCO.19.02103	2020	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.	CD274
32677947	10.1186/s12931-020-01437-6	2020	The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC.	CD274
32738861	10.31128/AJGP-11-19-5148	2020	Diagnosis and treatment of early lung cancer.	CD274
32751706	10.3390/ijms21155456	2020	Immune-Checkpoint Blockade Therapy in Lymphoma.	CD274
32759049	10.1016/j.intimp.2020.106852	2020	The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.	CD274
32778827	10.1038/s41591-020-1006-1	2020	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.	CD274
32783303	10.1111/pin.13000	2020	Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.	CD274
32870581	10.1111/ijlh.13326	2020	Characteristics of immunological synapse in mature B-cell neoplasms.	CD274
32871472	10.1016/j.compbiolchem.2020.107362	2020	N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.	CD274
32890601	10.1016/j.humpath.2020.08.008	2020	Comprehensive molecular genetic studies of Epstein-Barr virus-negative aggressive Natural killer-cell leukemia/lymphoma.	CD274
32992412	10.3760/cma.j.cn112151-20200205-00066	2020	[Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance].	CD274
33109533	10.21873/anticanres.14616	2020	EBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review.	CD274
33208970	10.1038/d41586-020-03154-y	2020	New lung-cancer drugs extend survival times.	CD274
33208971	10.1038/d41586-020-03155-x	2020	Better treatments for lung cancer that spreads to the brain.	CD274
33273548	10.1038/s41598-020-78152-1	2020	ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.	CD274
33443026	10.4049/immunohorizons.2000089	2020	Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist.	CD274
33745258		2020	PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population.	CD274
29946193	10.1038/s41375-018-0178-x	2019	Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.	CD274
30025443	10.4143/crt.2018.191	2019	Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.	CD274
30028010	10.1111/bjh.15514	2019	PD-1 is highly expressed by neoplastic B-cells in Richter transformation.	CD274
30033844	10.1080/10428194.2018.1480767	2019	Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.	CD274
30132131	10.1007/s00428-018-2438-6	2019	Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.	CD274
30268773	10.1016/j.pharmthera.2018.09.008	2019	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.	CD274
30286249	10.1111/his.13765	2019	Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma.	CD274
30321260	10.1093/ajcp/aqy130	2019	Lymphoepithelioma-Like Carcinoma of the Uterine Cervix: A Pathologic Study of Eight Cases With Emphasis on the Association With Human Papillomavirus.	CD274
30401947	10.1038/s41379-018-0173-9	2019	Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.	CD274
30411330	10.1111/cei.13232	2019	Monocytes show immunoregulatory capacity on CD4<sup>+</sup> T cells in a human in-vitro model of extracorporeal photopheresis.	CD274
30450620	10.1111/pin.12738	2019	Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorder.	CD274
30466764	10.1016/j.prp.2018.10.021	2019	Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.	CD274
30475455	10.1111/1759-7714.12917	2019	PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.	CD274
30538305	10.1038/s41571-018-0138-4	2019	A banner year for immunotherapy and targeted therapy.	CD274
30540571	10.1097/PAS.0000000000001198	2019	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.	CD274
30548240	10.1002/cncr.31871	2019	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.	CD274
30564891	10.1007/s00262-018-2282-1	2019	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.	CD274
30567732	10.4049/jimmunol.1800876	2019	BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.	CD274
30601579	10.1111/pin.12742	2019	Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.	CD274
30612418	10.3904/kjim.2018.179	2019	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.	CD274
30630986	10.3324/haematol.2018.205567	2019	Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma.	CD274
30636374	10.1111/resp.13463	2019	Somatic mutations and immune checkpoint biomarkers.	CD274
30637917	10.1002/pbc.27571	2019	Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.	CD274
30642552	10.1016/j.lungcan.2018.11.025	2019	Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.	CD274
30642913	10.1158/1078-0432.CCR-18-3904	2019	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.	CD274
30653748	10.4143/crt.2018.486	2019	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.	CD274
30666052	10.1038/s41379-018-0193-5	2019	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.	CD274
30672338	10.5858/arpa.2018-0149-RS	2019	Pulmonary Lymphoepithelioma-like Carcinoma.	CD274
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	CD274
30688388	10.1111/pin.12757	2019	Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma.	CD274
30723112	10.1182/bloodadvances.2018027672	2019	<i>MYD88</i> L265P mutation and <i>CDKN2A</i> loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.	CD274
30734108	10.1007/s00428-019-02528-6	2019	Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.	CD274
30745366	10.1158/2326-6066.CIR-18-0439	2019	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.	CD274
30770362	10.1182/bloodadvances.2018020602	2019	PD-L1 and tumor-associated macrophages in de novo DLBCL.	CD274
30783096	10.1038/s41408-019-0185-9	2019	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.	CD274
30819446	10.1016/j.critrevonc.2019.01.003	2019	Programmed cell death protein receptor and ligands in haematological malignancies - Current status.	CD274
30821551	10.1080/10428194.2019.1569231	2019	Modulation of immune checkpoint molecule expression in mantle cell lymphoma.	CD274
30824609	10.1158/1535-7163.MCT-18-1068	2019	HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.	CD274
30827742	10.1016/j.currproblcancer.2019.01.008	2019	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.	CD274
30851544	10.1016/j.leukres.2019.02.010	2019	Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.	CD274
30860441	10.2217/imt-2018-0173	2019	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.	CD274
30861172	10.1111/his.13857	2019	Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.	CD274
30890046	10.1080/16078454.2019.1590965	2019	Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.	CD274
30898647	10.1016/j.lfs.2019.03.040	2019	LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.	CD274
30910787	10.1182/blood-2018-10-879015	2019	<i>PD-L1</i> gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.	CD274
30917792	10.1186/s12885-019-5466-y	2019	The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.	CD274
30925928	10.1186/s12943-019-0977-3	2019	MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.	CD274
30938862	10.1111/his.13870	2019	A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.	CD274
30942469	10.3892/or.2019.7096	2019	Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.	CD274
30955977	10.1016/S0140-6736(18)32409-7	2019	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.	CD274
30975638	10.1182/blood.2018889931	2019	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.	CD274
30977285	10.1002/pbc.27757	2019	PD-L1 expression in pediatric Epstein-Barr virus positive classic Hodgkin lymphoma is not associated with 9p24.1 amplification.	CD274
31009388	10.1097/PAS.0000000000001254	2019	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.	CD274
31017033	10.1080/10428194.2019.1602266	2019	The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma.	CD274
31021376	10.1001/jamaoncol.2019.0393	2019	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.	CD274
31025831	10.1002/cncy.22140	2019	Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.	CD274
31039052	10.1200/JCO.18.02151	2019	Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.	CD274
31074879	10.1002/hon.2636	2019	Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.	CD274
31092922	10.1038/s41586-019-1215-2	2019	Targeting the CBM complex causes T<sub>reg</sub> cells to prime tumours for immune checkpoint therapy.	CD274
31098955	10.1007/s12539-019-00331-0	2019	PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation.	CD274
31107296	10.1097/LBR.0000000000000596	2019	Comparison of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration With Stylet Retracted Partially Versus Completely for Molecular Testing.	CD274
31123138	10.1136/jclinpath-2019-205727	2019	Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis.	CD274
31125630	10.1016/j.humpath.2019.05.007	2019	Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.	CD274
31130450	10.1016/j.cllc.2019.04.004	2019	Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.	CD274
31150165	10.1002/cam4.2316	2019	Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.	CD274
31151983	10.1182/blood.2019001043	2019	A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screening.	CD274
31166373	10.1590/1806-3713/e20180181	2019	Molecular profile of non-small cell lung cancer in northeastern Brazil.	CD274
31189800		2019	[Genetic Alterations Involving PD-L1/PD-L2 in Human Malignancies].	CD274
31197205	10.1038/s41374-019-0262-5	2019	PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.	CD274
31206665	10.1002/jcp.28884	2019	Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p.	CD274
31253857	10.1038/s41598-019-45479-3	2019	Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL.	CD274
31269329	10.1002/cam4.2394	2019	PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories.	CD274
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	CD274
31292525	10.1038/s41598-019-46473-5	2019	Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.	CD274
31343834	10.1111/crj.13063	2019	Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer.	CD274
31382969	10.1186/s12964-019-0391-x	2019	Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.	CD274
31394407	10.1016/j.virol.2019.07.024	2019	Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation.	CD274
31395597	10.1101/mcs.a004259	2019	Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma.	CD274
31408531	10.1002/hon.2664	2019	PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.	CD274
31456438	10.1080/14712598.2019.1659777	2019	Pembrolizumab for the treatment of diffuse large B-cell lymphoma.	CD274
31503548	10.1172/JCI127721	2019	Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development.	CD274
31509890	10.1111/1759-7714.13195	2019	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.	CD274
31584451	10.1097/PAI.0000000000000800	2019	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).	CD274
31640780	10.1186/s40425-019-0730-x	2019	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.	CD274
31644441	10.1097/COC.0000000000000608	2019	Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.	CD274
31655368	10.1016/j.lungcan.2019.10.017	2019	Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.	CD274
31679792	10.1016/j.prp.2019.152684	2019	Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.	CD274
31697809	10.1182/blood.2019002206	2019	The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.	CD274
31844419	10.1186/s11658-019-0190-9	2019	MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.	CD274
31856276	10.1182/blood.2019000889	2019	EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.	CD274
31934533	10.1155/2019/8586354	2019	Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.	CD274
27879989	10.1111/bjh.14432	2018	CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.	CD274
28967040	10.1007/s00277-017-3146-z	2018	Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.	CD274
29067721	10.1111/neup.12435	2018	The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.	CD274
29076134	10.1111/bjh.15009	2018	Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.	CD274
29112015	10.1097/PAS.0000000000000983	2018	PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.	CD274
29118007	10.1182/blood-2017-07-740993	2018	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.	CD274
29122656	10.1016/j.humpath.2017.10.029	2018	Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.	CD274
29128997	10.1007/s00277-017-3176-6	2018	PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.	CD274
29132694	10.1016/j.jaad.2017.09.015	2018	Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study.	CD274
29153898	10.1016/j.cllc.2017.10.014	2018	The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.	CD274
29189264	10.1097/PAI.0000000000000615	2018	Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma.	CD274
29247952	10.1016/j.biopha.2017.11.146	2018	Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.	CD274
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	CD274
29297942	10.1111/his.13461	2018	Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma.	CD274
29322203	10.1007/s00277-017-3226-0	2018	Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.	CD274
29338562	10.2217/nnm-2017-0296	2018	Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma.	CD274
29377256	10.1111/ejh.13033	2018	Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.	CD274
29380399	10.1111/his.13475	2018	Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.	CD274
29394125	10.1200/JCO.2017.77.3994	2018	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.	CD274
29415979	10.3960/jslrt.17037	2018	Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.	CD274
29428449	10.1016/j.leukres.2018.01.014	2018	PD-1 /PD-L1 checkpoint in hematological malignancies.	CD274
29449276	10.1182/blood-2017-07-796342	2018	Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.	CD274
29464311	10.1007/s00277-018-3266-0	2018	High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma.	CD274
29476608	10.1002/dc.23900	2018	Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.	CD274
29510739	10.1186/s40425-018-0326-x	2018	Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.	CD274
29540832	10.1038/s41388-018-0178-3	2018	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.	CD274
29545095	10.1016/S1470-2045(18)30144-X	2018	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.	CD274
29572000	10.1016/j.lungcan.2018.01.024	2018	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.	CD274
29593668	10.3389/fmicb.2018.00380	2018	Simulation Study of cDNA Dataset to Investigate Possible Association of Differentially Expressed Genes of Human THP1-Monocytic Cells in Cancer Progression Affected by Bacterial Shiga Toxins.	CD274
29598887	10.1016/j.prp.2018.03.001	2018	Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.	CD274
29695237	10.1186/s12885-018-4266-0	2018	Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation.	CD274
29695766	10.1038/s41416-018-0076-z	2018	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.	CD274
29748856	10.1007/s12185-018-2466-7	2018	CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.	CD274
29749542	10.3892/ijo.2018.4405	2018	The HDAC6 inhibitor ACY‑1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.	CD274
29762141	10.1097/PAS.0000000000001077	2018	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.	CD274
29856861	10.1371/journal.pone.0198634	2018	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.	CD274
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	CD274
29863955	10.1056/NEJMoa1716948	2018	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.	CD274
29876769	10.1007/s10238-018-0506-5	2018	Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.	CD274
29877291	10.2169/internalmedicine.9884-17	2018	Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.	CD274
29880615	10.1182/blood-2018-04-843714	2018	Mass cytometry of Hodgkin lymphoma reveals a CD4<sup>+</sup> regulatory T-cell-rich and exhausted T-effector microenvironment.	CD274
29895574	10.1158/2326-6066.CIR-17-0270	2018	Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.	CD274
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	CD274
29902298	10.1001/jamaoncol.2018.1701	2018	Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.	CD274
29936139	10.1016/j.ebiom.2018.06.010	2018	Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies.	CD274
29950244	10.7534/j.issn.1009-2137.2018.03.049	2018	[PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma -Review].	CD274
29970498	10.21873/anticanres.12662	2018	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.	CD274
29998979	10.3960/jslrt.18001	2018	The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.	CD274
30008296	10.1016/j.resinv.2018.04.004	2018	A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.	CD274
30026337	10.3324/haematol.2018.197194	2018	PD-L1<sup>+</sup> tumor-associated macrophages and PD-1<sup>+</sup> tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.	CD274
30054295	10.1182/blood-2018-01-829424	2018	Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.	CD274
30104397	10.1182/bloodadvances.2018021113	2018	Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.	CD274
30116872	10.1007/s00277-018-3467-6	2018	Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.	CD274
30135206	10.1074/jbc.RA118.004084	2018	The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.	CD274
30146693	10.1002/hon.2542	2018	Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.	CD274
30209121	10.1182/blood-2018-03-841015	2018	B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.	CD274
30214445	10.3389/fimmu.2018.01955	2018	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.	CD274
30247261	10.1097/PPO.0000000000000331	2018	Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.	CD274
30259911		2018	Predictive markers in lung cancer: a few hints for the practicing pathologist.	CD274
30261066	10.1371/journal.pone.0204870	2018	Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.	CD274
30290143	10.1016/j.cell.2018.09.007	2018	Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.	CD274
30305518	10.11406/rinketsu.59.2127	2018	[Genetic analysis and its clinical implication in adult T-cell leukemia/lymphoma].	CD274
30327655	10.3389/fimmu.2018.02264	2018	Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.	CD274
30359792	10.1016/j.ctrv.2018.10.006	2018	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?	CD274
30389217	10.1016/j.pathol.2018.08.011	2018	EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.	CD274
30429043	10.1016/j.lungcan.2018.09.010	2018	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.	CD274
30449068	10.1002/cam4.1875	2018	Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.	CD274
30458835	10.1186/s12967-018-1689-y	2018	Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.	CD274
30504313	10.1182/asheducation-2018.1.213	2018	Where does PD-1 blockade fit in HL therapy?	CD274
30541986	10.3960/jslrt.18034	2018	Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.	CD274
30595199	10.1016/S0007-4551(18)30390-4	2018	NA	CD274
27667773	10.1007/s40291-016-0237-9	2017	An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.	CD274
27686004	10.1080/10428194.2016.1219903	2017	Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.	CD274
27696202	10.1007/s00277-016-2818-4	2017	Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.	CD274
27696517	10.1002/ajh.24571	2017	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?	CD274
27881581	10.1158/1078-0432.CCR-16-1387	2017	Nivolumab in the Treatment of Hodgkin Lymphoma.	CD274
27966264	10.1002/hon.2375	2017	PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.	CD274
28104537	10.1016/j.jtho.2016.12.026	2017	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.	CD274
28114251	10.1097/PPO.0000000000000241	2017	Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy.	CD274
28125450	10.1097/PAS.0000000000000813	2017	Clinicopathological Study of 30 Cases of Peripheral T-cell Lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan.	CD274
28132868	10.1016/j.jtho.2017.01.019	2017	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.	CD274
28161001	10.1016/j.annpat.2016.12.005	2017	[Immune-checkpoint and hemopathies].	CD274
28188721	10.1016/j.cca.2017.02.005	2017	PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.	CD274
28242522	10.1016/j.ctrv.2017.01.009	2017	Targeting the programmed death-1 pathway in lymphoid neoplasms.	CD274
28249162	10.1016/j.celrep.2017.02.011	2017	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.	CD274
28259530	10.1016/j.ejso.2017.02.008	2017	Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis.	CD274
28344319	10.1038/leu.2017.103	2017	PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.	CD274
28349165	10.1007/s00262-017-1987-x	2017	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.	CD274
28402953	10.18632/oncotarget.16680	2017	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.	CD274
28403071	10.1097/MD.0000000000006398	2017	The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.	CD274
28414300	10.1172/JCI94196	2017	PD-L1 serves as a double agent in separating GVL from GVHD.	CD274
28423587	10.18632/oncotarget.15627	2017	The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.	CD274
28476792	10.21873/anticanres.11564	2017	PD-L1 Expression in Patients with Non-small Cell Lung Cancer.	CD274
28482851	10.1186/s13045-017-0474-3	2017	Checkpoint inhibitors in hematological malignancies.	CD274
28504999	10.1097/PAS.0000000000000851	2017	Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.	CD274
28511816	10.1016/j.it.2017.04.004	2017	Mechanisms of Immune Tolerance in Leukemia and Lymphoma.	CD274
28514441	10.1038/nature22396	2017	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.	CD274
28533311	10.1158/2326-6066.CIR-16-0221	2017	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.	CD274
28561682	10.1200/EDBK_175265	2017	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.	CD274
28581487	10.1038/labinvest.2017.54	2017	EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.	CD274
28620848	10.1007/s40273-017-0527-z	2017	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.	CD274
28624922	10.1007/s11523-017-0510-9	2017	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.	CD274
28659503	10.1183/16000617.0007-2017	2017	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series Pathology for the clinician Edited by Peter Dorfmüller and Alberto Cavazza.	CD274
28683452	10.1159/000471768	2017	Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.	CD274
28685821	10.1111/imm.12788	2017	PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.	CD274
28688724	10.1016/j.pathol.2017.05.003	2017	PD-1 and PD-L1 expression in bone and soft tissue sarcomas.	CD274
28689001	10.1016/j.clml.2017.06.014	2017	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.	CD274
28693793	10.1016/j.critrevonc.2017.06.001	2017	Biomarkers of response to PD-1/PD-L1 inhibition.	CD274
28760297	10.1016/j.clml.2017.02.022	2017	Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints.	CD274
28778363	10.1053/j.ackd.2017.05.006	2017	Kidney Toxicities Associated With Novel Cancer Therapies.	CD274
28819821	10.1007/s40265-017-0796-z	2017	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.	CD274
28822058	10.1007/s11899-017-0410-1	2017	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.	CD274
28835513	10.1634/theoncologist.2017-0078	2017	FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.	CD274
28842748	10.1007/s00277-017-3115-6	2017	PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.	CD274
28883281	10.11406/rinketsu.58.957	2017	Novel mechanism of immune evasion in cancer via structural variations of the PD-L1 gene.	CD274
28893733	10.1182/blood-2017-03-770719	2017	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.	CD274
28982883	10.21873/anticanres.12001	2017	Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.	CD274
29018115	10.1128/mBio.00917-17	2017	Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes.	CD274
29057919	10.1038/s41598-017-10946-2	2017	Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.	CD274
29167175	10.1182/blood-2017-06-781989	2017	Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.	CD274
29190182	10.1080/08880018.2017.1383542	2017	Checkpoint inhibition in pediatric hematologic malignancies.	CD274
29222272	10.1182/asheducation-2017.1.310	2017	Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.	CD274
29246182	10.1186/s40880-017-0262-z	2017	Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.	CD274
29259344	10.1038/nrc.2017.124	2017	Targeted therapies: Strategies for mature T cell cancers.	CD274
26426431	10.1111/his.12882	2016	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.	CD274
26432723	10.1016/j.bbcan.2015.09.002	2016	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.	CD274
26560962	10.1111/ejh.12697	2016	Checkpoint inhibitors in Hodgkin's lymphoma.	CD274
26678894	10.1007/s13277-015-4622-5	2016	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.	CD274
26807978	10.1111/febs.13668	2016	Immune checkpoint blockade in lymphoid malignancies.	CD274
26844985	10.1097/CCO.0000000000000272	2016	Experimental treatment strategies in primary cutaneous T-cell lymphomas.	CD274
26850007	10.1002/gcc.22345	2016	Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.	CD274
26901614	10.1016/j.ejca.2015.12.033	2016	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.	CD274
26984449	10.1634/theoncologist.2015-0507	2016	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.	CD274
27026676	10.1634/theoncologist.2015-0498	2016	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.	CD274
27030389	10.1182/blood-2015-12-686550	2016	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.	CD274
27045512	10.1016/j.humpath.2016.03.005	2016	Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.	CD274
27069084	10.1200/JCO.2016.66.4482	2016	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.	CD274
27070269	10.1080/13543784.2016.1175433	2016	Programming the immune checkpoint to treat hematologic malignancies.	CD274
27105512	10.18632/oncotarget.8847	2016	High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.	CD274
27107327	10.1016/j.ejca.2016.03.012	2016	High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma.	CD274
27147575	10.18632/oncotarget.9061	2016	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.	CD274
27158757	10.1097/PAS.0000000000000653	2016	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.	CD274
27225694	10.1158/1078-0432.CCR-15-3101	2016	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.	CD274
27229745	10.1007/s40265-016-0588-x	2016	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?	CD274
27268263	10.1182/blood-2015-11-683003	2016	Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.	CD274
27269947	10.1200/JCO.2015.65.9789	2016	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.	CD274
27281199	10.1038/nature18294	2016	Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.	CD274
27338100	10.1182/blood-2015-08-662783	2016	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.	CD274
27341313	10.1111/bjh.14201	2016	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.	CD274
27354476	10.1200/JCO.2016.67.3467	2016	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.	CD274
27376797	10.1007/s11596-016-1585-8	2016	A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.	CD274
27418641	10.1182/blood-2016-02-698936	2016	PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.	CD274
27419920	10.1002/ajh.24485	2016	The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.	CD274
27473193	10.1007/s00277-016-2764-1	2016	Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety.	CD274
27564404	10.1111/cas.13065	2016	An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.	CD274
27595782	10.1007/s00428-016-2011-0	2016	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.	CD274
27708232	10.18632/oncotarget.12363	2016	A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.	CD274
27737703	10.1186/s13045-016-0341-7	2016	PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.	CD274
27737878	10.1158/2326-6066.CIR-16-0201	2016	Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.	CD274
27753058		2016	Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?	CD274
27753543	10.1080/15384101.2016.1245249	2016	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.	CD274
27861156	10.18632/oncotarget.13411	2016	An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.	CD274
27861596	10.1371/journal.pone.0166266	2016	PD-L1 Status in Refractory Lymphomas.	CD274
28031823	10.1186/s40425-016-0201-6	2016	Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.	CD274
25393674	10.3109/10428194.2014.985673	2015	Structural genomic alterations in primary mediastinal large B-cell lymphoma.	CD274
25482239	10.1056/NEJMoa1411087	2015	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.	CD274
25712539	10.1002/path.4522	2015	Recurrent genomic rearrangements in primary testicular lymphoma.	CD274
25730880	10.1073/pnas.1500712112	2015	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.	CD274
25823918	10.1016/j.clinthera.2015.02.018	2015	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.	CD274
25824455	10.1111/bjh.13397	2015	Immune checkpoint inhibition in lymphoid disease.	CD274
25862146	10.1016/j.lungcan.2015.03.017	2015	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.	CD274
26004934	10.1007/s00277-015-2403-2	2015	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.	CD274
26019170	10.1158/1078-0432.CCR-15-0016	2015	Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.	CD274
26047524	10.1016/j.coph.2015.05.011	2015	PD-1/PD-L1 inhibitors.	CD274
26049755	10.1097/MOH.0000000000000158	2015	Targeting immune checkpoints in lymphoma.	CD274
26049756	10.1097/MOH.0000000000000155	2015	Genomic alterations underlying immune privilege in malignant lymphomas.	CD274
26135560	10.1097/PAS.0000000000000473	2015	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.	CD274
26239088	10.1182/blood-2015-02-629600	2015	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.	CD274
26254381		2015	Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.	CD274
26362649	10.1186/s13073-015-0218-3	2015	Gene expression meta-analysis reveals immune response convergence on the IFNγ-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma.	CD274
26419961	10.1158/2326-6066.CIR-15-0089	2015	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.	CD274
26449653	10.1186/s13045-015-0213-6	2015	Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.	CD274
26522856	10.1556/650.2015.30260	2015	[Novel treatment options in relapsed and refracter Hodgkin lymphomas].	CD274
26599546	10.1371/journal.pone.0139663	2015	Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.	CD274
26686046	10.1016/S2352-3026(15)00150-7	2015	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.	CD274
24359606	10.5414/np300698	2014	PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).	CD274
24497532	10.1182/blood-2013-10-535443	2014	Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.	CD274
24610827	10.1158/1078-0432.CCR-13-3007	2014	Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.	CD274
24732592	10.1038/leu.2014.137	2014	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.	CD274
24780756	10.1158/0008-5472.CAN-13-3596	2014	Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.	CD274
23223433	10.1182/blood-2012-10-385591	2013	The role of B7 family molecules in hematologic malignancy.	CD274
23508008	10.3324/haematol.2012.071340	2013	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.	CD274
23610619	10.1177/2040620712471553	2013	The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.	CD274
23660624	10.1038/leu.2013.118	2013	Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.	CD274
23966158	10.4161/cc.25922	2013	Histone H2AX suppresses translocations in lymphomas of Eμ-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes.	CD274
24404580	10.1016/j.ajpath.2013.08.030	2013	The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.	CD274
22094231	10.1097/DAD.0b013e31821c35cb	2012	Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides.	CD274
22271878	10.1158/1078-0432.CCR-11-1942	2012	Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.	CD274
22462616	10.3109/10428194.2012.673228	2012	Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.	CD274
22547582	10.1182/blood-2012-02-411678	2012	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.	CD274
22661084	10.4049/jimmunol.1102277	2012	B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels.	CD274
21368758	10.1038/nature09754	2011	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.	CD274
21540239	10.1158/1078-0432.CCR-10-2660	2011	Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.	CD274
21851845	10.1016/j.humimm.2011.07.308	2011	Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.	CD274
22169317		2011	[Research update on PD-1/PD-L1 pathway in hematological diseases].	CD274
20628145	10.1182/blood-2010-05-282780	2010	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.	CD274
20639904	10.1038/onc.2010.280	2010	The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with γ-radiation-induced T-cell lymphoblastic lymphomas.	CD274
18830259	10.1038/leu.2008.272	2009	PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.	CD274
19393833	10.1053/j.seminoncol.2009.02.007	2009	Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.	CD274
19597183	10.1182/blood-2009-04-216671	2009	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.	CD274
19703193	10.1111/j.1349-7006.2009.01302.x	2009	B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.	CD274
18203952	10.1182/blood-2007-05-085159	2008	PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.	CD274
19058313	10.3748/wjg.14.6853	2008	Hepatoma cells up-regulate expression of programmed cell death-1 on T cells.	CD274
19088198	10.1073/pnas.0810958105	2008	Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).	CD274
16403912	10.1182/blood-2005-08-3376	2006	Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.	CD274
